ALX Oncology Holdings Inc. (NASDAQ: ALXO) is a Healthcare company (Biotechnology) with a market capitalization of $139M. The Maz Rating grades it against the other companies in its sector.
ALX Oncology Holdings Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.00, ALX Oncology Holdings Inc. trades at 1.1x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -73.4%, return on invested capital of -61.2% and a free cash flow yield of -49.4%. On the balance sheet: a debt-to-equity ratio of 0.08 and a current ratio of 8.04. Over the past 52 weeks the share price ranged from $0.86 to $2.66, with a beta of 0.40.
ALX Oncology Holdings Inc. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 6 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, ALX Oncology Holdings Inc. (ALXO) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 4.84% / 30% · (Cash+Inv) / Mkt Cap (36m) 73.2% / 30% · Interest income / Revenue 137900000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 4.84% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 73.2% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 137900000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 4.84% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 73.2% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 137900000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 5.40% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 85.1% / 33.33% · Receivables / Avg Assets (4Q) 0.05% / 33.33% · Interest income / Revenue 137900000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 6.30% / 33.33% · (Cash+ST Inv) / Total Assets 95.2% / 33.33% · (Cash+Recv) / Total Assets 95.2% / 33.33% · Interest income / Revenue 137900000.0% / 5% | Fail |
No. As of September 2026, ALX Oncology Holdings Inc. (ALXO) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. ALX Oncology Holdings Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 137900000.0% of each dividend: ALX Oncology Holdings Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.